Search results
Showing 151 to 165 of 381 results for depression
This guideline covers mental health rehabilitation for adults with complex psychosis. It aims to ensure people can have rehabilitation when they need it and promotes a positive approach to long-term recovery. It includes recommendations on organising rehabilitation services, assessment and care planning, delivering programmes and interventions, and meeting people’s physical healthcare needs.
Depression: management of depression in primary and secondary care (CG23)
This guidance has been updated and replaced by NICE guideline CG90.
This quality standard covers diagnostic reporting and the organisation of haematological cancer services for people of all ages (children, adults and young people) and managing haematological cancers in adults and young people (aged 16 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS150Show all sections
Sections for QS150
Chronic heart failure in adults: diagnosis and management (NG106)
This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.
Extracranial to intracranial bypass for intracranial atherosclerosis (HTG452)
Evidence-based recommendations on extracranial to intracranial bypass for intracranial atherosclerosis. This involves joining a blood vessel from outside the skull to one inside the skull to bypass a narrowed or partially blocked vessel.
This guideline covers diagnosing and managing Lyme disease. It aims to raise awareness of when Lyme disease should be suspected and ensure that people have prompt and consistent diagnosis and treatment. It does not cover preventing Lyme disease.
Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin (Copegus) for treating chronic hepatitis C in children and young people.
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)
Evidence-based recommendations on nemolizumab (Nemluvio) for treating moderate to severe atopic dermatitis in people 12 years and over.
Renal replacement therapy and conservative management (NG107)
This guideline covers renal replacement therapy (dialysis and transplantation) and conservative management for people with chronic kidney disease stages 4 and 5. It aims to improve quality of life by making recommendations on planning, starting and switching treatments, and coordinating care.
This guideline covers diagnosing and managing rheumatoid arthritis. It aims to improve quality of life by ensuring that people with rheumatoid arthritis have the right treatment to slow the progression of their condition and control their symptoms. People should also have rapid access to specialist care if their condition suddenly worsens.
Insertion of a magnetic bead band for faecal incontinence (HTG336)
Evidence-based recommendations on insertion of a magnetic-bead band for faecal incontinence. This involves placing a ring of magnetic beads into a tunnel made around the anus to prevent incontinence.
View recommendations for HTG336Show all sections
raised blood pressure or cholesterol levels or those experiencing mild depression, anxiety or stress; or by age, gender, race or...
Antisocial behaviour and conduct disorders in children and young people (QS59)
This quality standard covers recognising and managing antisocial behaviour and conduct disorders in children and young people. It describes high-quality care in priority areas for improvement.
View quality statements for QS59Show all sections
Sections for QS59
- Quality statements
- Quality statement 1: Early intervention
- Quality statement 2: Comprehensive assessment
- Quality statement 3: Improving access to services
- Quality statement 4: Parent or carer training
- Quality statement 5: Multimodal interventions
- Quality statement 6: Monitoring adverse effects of pharmacological interventions
- Update information
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
The EQ-5D is a short questionnaire used to understand how a person’s health affects their quality of life. It is used in health research and to help inform decisions about healthcare treatments.